GlassScriptPhysician profile
Ramesh B Peramsetty
NPI 1730175969
$6,897.65
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $561 · 2021: $715 · 2022: $232 · 2023: $4,836 · 2024: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,231 · Travel and Lodging: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,230.87 |
| Travel and Lodging | $1,920.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $4,897.70 | 2021-2024 | Xeomin |
| Novo Nordisk INC | $237.97 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $229.45 | 2019-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $211.78 | 2021-2024 | |
| Astellas Pharma US INC | $187.29 | 2020-2024 | Veozah |
| Allergan, INC. | $179.72 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $146.58 | 2020-2022 | |
| Amarin Pharma, INC. | $116.66 | 2020-2021 | |
| Revance Therapeutics, INC. | $95.94 | 2024 | Daxxify |
| Merck Sharp & Dohme LLC | $76.77 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $74.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.66 | 2019-2021 | |
| Dexcom, INC. | $45.49 | 2021-2023 | Dexcom G6 Transmitter |
| Opko Pharmaceuticals, LLC | $44.29 | 2020-2021 | |
| Amgen INC. | $43.56 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.68 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $38.52 | 2023-2024 | Farxiga |
| Melinta Therapeutics, LLC | $29.76 | 2019 | |
| Pfizer INC. | $28.37 | 2020-2024 | |
| Hikma Pharmaceuticals USA | $26.81 | 2019 | |
| Ardelyx, INC. | $24.75 | 2024 | Ibsrela |
| Galderma Laboratories, L.P. | $17.27 | 2023 | Dysport |
| Arbor Pharmaceuticals, INC. | $14.54 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.14 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.71 | 2021 | |
| Mylan Specialty L.P. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Peramsetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.